TG-89

CAS No. 936091-56-4

TG-89( —— )

Catalog No. M33687 CAS No. 936091-56-4

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 34 In Stock
5MG 63 In Stock
10MG 98 In Stock
25MG 164 In Stock
50MG 231 In Stock
100MG 312 In Stock
200MG 429 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TG-89
  • Note
    Research use only, not for human use.
  • Brief Description
    TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
  • Description
    JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    FLT
  • Recptor
    FLT | JAK | c-RET
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    936091-56-4
  • Formula Weight
    510.65
  • Molecular Formula
    C26H34N6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cc1cnc(Nc2cccc(CN3CCOCC3)c2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Glenn Noronha, et al. Bi-aryl meta-pyrimidine inhibitors of kinases. Patent. US20110212077A1.
molnova catalog
related products
  • (E/Z)-Zotiraciclib

    (E/Z)-Zotiraciclib inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.

  • JI6

    JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ~40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.

  • XL019

    XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM.